Neurostimulation Devices Market Revenue is Predicted to Surpass a Valuation of US$ 36.5 billion by 2032, States by Market.us
May 24, 2023 06:57 ET
|
Market.Us
New York, May 24, 2023 (GLOBE NEWSWIRE) -- The Neurostimulation Devices Market stood at US$ 11.1 billion in 2022 and the global market is projected to reach US$ 36.5 billion by 2032. The global...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 07:30 ET
|
Praxis Precision Medicines, Inc.
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting
April 19, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events
April 17, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 07, 2023 08:00 ET
|
Praxis Precision Medicines, Inc.
Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 09, 2022 16:01 ET
|
Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 study topline results for essential tremor expected in 1Q23 PRAX-222 EMBRAVE study for SCN2A-DEE to initiate in 4Q22; topline results for initial dose cohort expected in...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
Praxis Precision Medicines, Inc.
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results...
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients
May 09, 2022 16:01 ET
|
Praxis Precision Medicines, Inc.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by...
Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology Annual Meeting
April 01, 2022 09:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...